Captrust Financial Advisors Acquires 21,523 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Captrust Financial Advisors boosted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 116.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,062 shares of the company’s stock after buying an additional 21,523 shares during the period. Captrust Financial Advisors owned approximately 0.08% of scPharmaceuticals worth $142,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SCPH. AIGH Capital Management LLC boosted its stake in shares of scPharmaceuticals by 1.2% in the 4th quarter. AIGH Capital Management LLC now owns 4,174,367 shares of the company’s stock valued at $14,777,000 after purchasing an additional 50,000 shares in the last quarter. King Luther Capital Management Corp increased its stake in shares of scPharmaceuticals by 28.4% in the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock valued at $10,117,000 after acquiring an additional 632,120 shares in the last quarter. Nantahala Capital Management LLC increased its stake in shares of scPharmaceuticals by 33.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,540,000 after acquiring an additional 250,000 shares in the last quarter. Rice Hall James & Associates LLC grew its position in scPharmaceuticals by 59.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock valued at $3,503,000 after purchasing an additional 367,970 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in scPharmaceuticals by 16.7% during the 4th quarter. Geode Capital Management LLC now owns 750,493 shares of the company’s stock worth $2,657,000 after acquiring an additional 107,151 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Stock Up 5.1%

Shares of SCPH opened at $3.51 on Friday. The firm has a market cap of $185.30 million, a P/E ratio of -1.85 and a beta of 0.17. scPharmaceuticals Inc. has a 1 year low of $1.94 and a 1 year high of $5.65. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock has a 50 day simple moving average of $2.63 and a two-hundred day simple moving average of $3.15.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The company had revenue of $11.75 million for the quarter, compared to analysts’ expectations of $11.63 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. On average, analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

SCPH has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, March 20th. Maxim Group decreased their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.